Publication Name	World Journal of Clinical Cases
Manuscript ID	47215
Country	China

Received	2019-03-11 08:02
Peer-Review Started	2019-03-11 09:05
To Make the First Decision	2019-05-06 00:10
Return for Revision	2019-05-10 09:24
Revised	2019-06-02 08:06
Second Decision	2019-06-24 03:59
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief	2019-06-27 06:36
Articles in Press	2019-06-27 06:36
Publication Fee Transferred
Edit the Manuscript by Language Editor	2019-07-03 01:22
Typeset the Manuscript	2019-07-22 03:52
Publish the Manuscript Online	2019-07-26 10:13

ISSN	2307-8960 (online)
Open Access	This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright	© The Author(s) 2019. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Gastroenterology & Hepatology
Manuscript Type	Minireviews
Article Title	Antiviral treatment for chronic hepatitis B: Safety, effectiveness, and prognosis
Manuscript Source	Invited Manuscript
All Author List	Ya-Li Wu, Cheng-Li Shen and Xin-Yue Chen
ORCID	Author(s) ORCID Number Ya-Li Wu http://orcid.org/0000-0002-7820-2521 Cheng-Li Shen http://orcid.org/0000-0003-4731-2872 Xin-Yue Chen http://orcid.org/0000-0003-3212-2398
Funding Agency and Grant Number	Funding Agency Grant Number The Thirteenth Five-Year Major Science and Technology Projects 2017ZX10202201 The Thirteenth Five-Year Major Science and Technology Projects 2017ZX10201021-001-008 The Capital Characteristic Clinical Application Research and Extension of Achievements Z151100004015181 The Capital Characteristic Clinical Application Research and Extension of Achievements Z161100000516018 The Capital Health Research and Development Projects 2016-1-2183 Special Fund for Clinical Medical Research of the Chinese Medical Association 15030270615
Corresponding Author	Xin-Yue Chen, MD, Professor, International Medical Department, Beijing Youan Hospital, Capital Medical University, No. 8 of Xitoutiao Outside Youanmen, Fengtai District, Beijing 10069, China. chenxydoc@163.com
Key Words	Chronic hepatitis B; Antiviral treatment endpoint; Safety; Prognosis improvement; Hepatitis B surface antigen clearance;
Core Tip	Different antiviral treatment endpoints have different degrees of improvement in disease prognosis. Hepatitis B surface antigen (HBsAg) clearance has been recommended as an optimal endpoint of antiviral treatment by the latest chronic hepatitis B management guidelines. It can not only lead to safer drug withdrawal but also significantly improves prognosis. However, HBsAg clearance rate is low using the conventional single drug treatment and fixed course regimens. So individualized treatment strategies should be implemented according to the specific conditions of patients. This article reviews the different antiviral treatment endpoints in terms of the safety of drug withdrawal, improvements in prognosis and how to improve HBsAg clearance.
Publish Date	2019-07-26 10:13
Citation	Wu YL, Shen CL, Chen XY. Antiviral treatment for chronic hepatitis B: Safety, effectiveness, and prognosis. World J Clin Cases 2019; 7(14): 1784-1794
URL	https://www.wjgnet.com/2307-8960/full/v7/i14/1784.htm
DOI	https://dx.doi.org/10.12998/wjcc.v7.i14.1784

Full Article (PDF)	WJCC-7-1784.pdf
Full Article (Word)	WJCC-7-1784.docx
Manuscript File	47215-Review_Edited.docx
Answering Reviewers	47215-Answering reviewers.pdf
Audio Core Tip	47215-Audio core tip.mp3
Conflict-of-Interest Disclosure Form	47215-Conflict-of-interest statement.pdf
Copyright License Agreement	47215-Copyright license agreement.pdf
Approved Grant Application Form(s) or Funding Agency Copy of any Approval Document(s)	47215-Grant application form(s).pdf
Non-Native Speakers of English Editing Certificate	47215-Language certificate.pdf
Peer-review Report	47215-Peer-review(s).pdf
Scientific Misconduct Check	47215-Scientific misconduct check.pdf
Scientific Editor Work List	47215-Scientific editor work list.pdf